期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

生物制剂治疗白塞病的研究新进展 被引量：2

原文传递
导出
摘要 白塞病（Behcet’s disease，BD）是一种全身性、慢性、血管炎症性疾病，大、中、小血管均可以受累，主要表现为复发性口腔溃疡、生殖器溃疡及眼炎，也可以累及皮肤、关节、神经系统、消化系统、肺及肾脏等器官。本病在东亚、中东和地中海地区发病率较高，安那托利亚的土耳其人的发病率最高，为（100-370）／10万^[1]，我国发病率在北方约为14／10万，南方比北方少^[2]。BD患者男性多于女性，且病情比女性重，尤其是眼部受累的症状^[3]，其中约50％左右的BD患者眼睛受累，致盲率可达25％，
作者 陈小云 张莉芸 刘雅妮 霍月红
机构地区 山西医科大学第二医院风湿免疫科
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2009年第1期57-59,共3页 Chinese Journal of Rheumatology
基金 山西省科技攻关基金（2007031093-4） 太原市科技局科技兴市项目（0504020）
关键词 白塞病 生物制剂 地区发病率 复发性口腔溃疡 治疗 炎症性疾病 生殖器溃疡 主要表现
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献20

  • 1Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet's disease. Semin Arthritis Rheum, 1998, 27:197-217.
  • 2陈珠灏.实用内科学.11版.北京:人民卫生出版社,2002.
  • 3Evereklioglu C. Current concepts in the etiology and treatment of Behcet's disease. Surv Ophthalmol, 2005, 50: 297-350.
  • 4Tugal-Tutkun IS, Onal SNAL. Uveitis in Behcet's disease: an analysis of 880 patients. Am J Ophthahnol, 2004, 138: 373-380.
  • 5Kaklamani VG, Kaklamanis PG. Treatment of Behcet's disease: an update. Semin Arthritis Rheum, 2001, 30: 299-312.
  • 6Tsambaos D, Eichelberg D, Goos M. Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res, 1986, 278: 335-336.
  • 7Ergun T, Ince U, Eksioglu-Demiralp E, et al. HSP 60 expression in mucocutaneous lesions of Behcet's disease. J Am Acad Dermatol, 2001, 45: 904-909.
  • 8Bank I, Duvdevani M, Livneh A. Expansion of gammadeha T- cells in Behcet's disease: role of disease activity and microbial flora in oral ulcers. J Lab Clin Med, 2003, 141: 33-40.
  • 9Triolo G, Accardo-Palumbo A, Dieli F, et al. V gamma 9/Vdelta 2 T lymphocytes in Italian patients with Behcet's disease: evidence for expansion, and tumour necrosis factor receptor Ⅱ and interleukin-12 receptor beta 1 expression in active disease. Arthritis Res Ther, 2003, 5: R262-R268.
  • 10杨玲,饶春明,杜贤宇,徐振山,周业亭,刘长暖,宋礼华.三种α干扰素亚型单抗的特性鉴定[J].上海免疫学杂志,2003,23(1):55-57. 被引量：4

二级参考文献43

  • 1宋礼华,王荣海,付永标,杨玲,杜贤宇,徐键.单克隆抗体亲和层析纯化人白细胞干扰素的研究[J].生命科学,1996,8(3):47-48. 被引量：2
  • 2萨姆布鲁克J 弗里奇EF 曼尼阿蒂斯T 金冬雁 黎孟枫 译.分子克隆实验指南[M].第2版[M].北京:科学出版社,1996..
  • 3Pestka S, Langer JA, Zoon KC, et al. lntefferons and their action[J].Annu Rev Biochem, 1987,56:727.
  • 4Branca AA. Interferon receptor in vitro[J]. Cell Devel Biol, 1988,24:155.
  • 5Fish EN,Banerjee K,Stebbing N. Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cell[J].Biochem Biophys Res Commun, 1983,112 : 537.
  • 6Shearer M ,Taglor JP, Griffin D. Monoclonal antibodies that distinguish between subspecies of human interferon and that detect interferonoligomers[J]. J Immunol, 1984,133:3096.
  • 7宋礼华 杨玲 傅永标 等.两株人a干扰素单克隆抗体杂交瘤建株研究[J].安徽农业大学学报,1993,20:11-11.
  • 8von Wussow P, Hehlmann R, Hochhau T. Roferon (rlFN-α2a) is more immunogenic than intren A (rlFN-α2b) in patients with chronic myelogenous leukemia[J]. J IFN Res, 1994,14:217.
  • 9Overall ML, Hertzog PJ. Functional analysis of interferon subtypes using monoclonal antibodies to interferen-4A: subtype reactivity, neutralization of biological activities and epitope analysis[J]. Mol Immunol,1991,29:391.
  • 10Staehelin T, Stahli C, Hobbs DS, et al. A rapid quantitative assay of high sensitivity for human leukocyte interferon with monoclonal antibodies[J]. Methods Enzymol,Aead Press, New York, 1981,79:589.

共引文献25

同被引文献22

  • 1张卓莉,彭劲民,侯小萌,董怡.1996例白塞病患者的临床荟萃分析[J].北京医学,2007,29(1):10-12. 被引量：67
  • 2Sommer A, Ahmeyer P, Kreuter A. A ease of mucocutaneous Behqet'8 disease re, sponding to etanereept [J]. J Am Acad Dermatol, 2005, 52:717-719.
  • 3Estrach C, Mpofu S, Moots RJ. Behcet' s syndrome: response to infliximab after failure of etanercept [J]. Rheumatology, 2002, 41:1213-1214.
  • 4Handa T, Tsunekawa H, Yoneda M. Long-term remission of ocular and extraocular manifestations in Behqet' s disease using infliximab [ J ]. Clin Exp Rheumatol. 2011, 29(4 Suppl 67) :S58-63.
  • 5Keino H, Okada AA, Watanabe T, et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet' s disease on infliximab therapy [J]. Br J Ophthalmol, 2011,95 : 1245-1250.
  • 6Sugita S, Yamada Y, Mocbizuki M. Relationshi Pbetween serum infliximab levels and acute uveitis attacks in patients with Behcet disease [ J ]. Br J Ophthalmol, 2011, 95:549-552.
  • 7Yamada Y, Sugita S, Tanaka H. Timing of recurrent uveitis in patients with Behcet' s disease receiving infliximab treatment [J]. Br J Ophthalmol, 2011, 95 : 205 -208.
  • 8Giardina A, Ferrante A, Ciccia F. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behset' s disease refractory to standard immunosuppressive drugs [ J ]. Rheumatol Int. 2011, 31:33-37.
  • 9Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active behcet' s uveitis: an open-label trial [J]. Rheumatol Int, 2008, 29:53-57.
  • 10Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behcet' s uveitis: advantages and controversial aspects [ J ]. Ann N Y Acad Sci, 2007, 1110:474-484.

引证文献2

二级引证文献10

中华风湿病学杂志
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部